Novo Nordisk Aims for U.S. Approval for Tresiba

REPLAY VIDEO
Your next video will start in
Pause
  • Info

  • Comments

Jan. 31 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk A/S stuck to its target of getting U.S. approval for the diabetes treatment Tresiba in the first half as it’s counting on the product to reach higher 2013 forecasts. She speaks on Bloomberg Television's "The Pulse."

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change